Literature DB >> 8014114

Effects of intravenous infusion of dopamine on tumor blood flow in rat subcutis.

S Tanda1, K Hori, S Saito, Q H Zhang, H C Li, M Suzuki.   

Abstract

To determine the effects of intravenous administration of dopamine hydrochloride (DA) on tumor blood flow (TBF), we measured the blood flow of normal subcutaneous tissue and subcutaneous tumor (LY-80, a variant of Yoshida sarcoma) in enflurane-anesthetized male Donryu rats using a hydrogen clearance method. Measurements were made before and during intravenous infusion of DA at a rate of 5 micrograms/kg/min, while recording the mean arterial blood pressure of the rats. Under mild hypertension induced by DA, the blood flow of normal subcutis decreased and TBF increased significantly. SCH-23390, an antagonist of the DA1 receptor, inhibited the enhancement of TBF by DA; while domperidone, an antagonist of the DA2 receptor, did not modify the effects of DA. In experimental chemotherapy against the tumor using adriamycin (ADM) 5 mg/kg i.v., only the combination of DA and ADM significantly inhibited the tumor growth. Moreover, DA reduced the weight loss caused by ADM. These results indicate that DA could have a role in increasing TBF and possibly enhance drug delivery to tumors. Moreover, it appears that the DA1 receptor contributes, at least in part, to the enhanced blood flow in rat subcutaneous tumor following DA administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014114      PMCID: PMC5919505          DOI: 10.1111/j.1349-7006.1994.tb02395.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  37 in total

1.  The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse.

Authors:  D G Hirst; V K Hirst; K M Shaffi; V E Prise; B Joiner
Journal:  Int J Radiat Biol       Date:  1991 Jul-Aug       Impact factor: 2.694

2.  Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat.

Authors:  J A Winston; R Safirstein
Journal:  Am J Physiol       Date:  1985-10

3.  Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure.

Authors:  R A Zlotecki; Y Boucher; I Lee; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

4.  Role of kidney dopamine in the natriuretic response to volume expansion in rats.

Authors:  S S Hegde; A L Jadhav; M F Lokhandwala
Journal:  Hypertension       Date:  1989-06       Impact factor: 10.190

Review 5.  Chemical modification of tumour blood flow.

Authors:  R L Jirtle
Journal:  Int J Hyperthermia       Date:  1988 Jul-Aug       Impact factor: 3.914

6.  [Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report)].

Authors:  H Sato; A Wakui; M Hoshi; M Kurihara; M Yokoyama; H Shimizu
Journal:  Gan To Kagaku Ryoho       Date:  1991-03

7.  Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin II.

Authors:  J A Goldberg; M S Bradnam; D J Kerr; J H McKillop; R G Bessent; C S McArdle; N Willmott; W D George
Journal:  Nucl Med Commun       Date:  1987-12       Impact factor: 1.690

Review 8.  The use of blood flow modifiers to improve the treatment response of solid tumors.

Authors:  M R Horsman; D J Chaplin; J Overgaard
Journal:  Radiother Oncol       Date:  1991       Impact factor: 6.280

9.  A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II.

Authors:  M Suzuki; K Hori; I Abe; S Saito; H Sato
Journal:  J Natl Cancer Inst       Date:  1981-09       Impact factor: 13.506

Review 10.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.